Abstract
Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome resulting from the translocation t(9-22) producing the chimeric 190 and 210 kDa BCR – ABL fusion proteins. Evolution of the CML to the more agressive acute myelogenous leukemia (AML) is accompanied by increased cellular proliferation and genomic instability at the cytogenetic level. We hypothezised that genomic instability at the nucleotide level and spontaneous error in DNA replication may also contribute to the evolution of CML to AML. Murine Ba/F3 cell line was transfected with the p190 and p210-encoding BCR – ABL oncogenes, and spontaneous mutation frequency at the Na-K-ATPase and the hypoxanthine guanine phosphoribosyl transferase (HPRT) loci were measured. A significant 3 – 5-fold increase in mutation frequency for the transfected cells relative to the untransfected control cells was found. Furthermore, we observed that BCR – ABL transfection induced an overexpression of DNA polymerase β, the most inaccurate of the mammalian DNA polymerases, as well as an increase in its activity, suggesting that inaccuracy of DNA replication may account for the observed mutator phenotype. These data suggest that the Philadelphia abnormality confers a mutator phenotype and may have implications for the potential role of DNA polymerase β in this process.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley R, Bennardo T, Novault S, Bonnet M, Gisselbrecht S, Varet B and Turhan A. . 1998 Oncogene 16: 489–496.
Ahuja H, Bar-Eli M, Advani S, Benchimol S and Cline M. . 1989 Proc. Natl. Acad. Sci. USA 86: 6783–6787.
Ahuja H, Bar-Eli M, Arlin Z, Allen S, Goldman J, Snyder D, Foti A and Cline M. . 1991 J. Clin. Invest. 87: 2042–2047.
Bernstein R. . 1988 Semin. Hematol. 25: 20–34.
Bouayadi K, Hoffmann J, Fons P, Tiraby M, Reynes J and Cazaux C. . 1997 Cancer Res. 57: 110–116.
Cahill D, Lengauer C, Yu J, Riggins G, Willson J, Markowitz S, Kinzler K and Vogelstein B. . 1998 Nature 392: 300–303.
Canitrot Y, Cazaux C, Fréchet M, Bouayadi K, Lesca C, Salles B and Hoffmann JS . 1998 Proc. Natl. Acad. Sci. USA 95: 12586–12590.
Collins S, Howard M, Andrews D, Agura E and Radich J. . 1989 Blood 73: 1028–1032.
Copeland W, Chen M and Wang T. . 1992 J. Biol. Chem. 267: 21459–21464.
Feinstein E, Cimino G, Gale R, Alimena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berreri A and Canaani E. . 1991 Proc. Natl. Acad. Sci. USA 88: 6293–6297.
Fialkow P, Jacobson R and Papayannopoulou T. . 1977 Am. J. Med. 63: 125–130.
Fornace A, Zmudzka B, Hollander M and Wilson S. . 1989 Mol. Cell. Biol. 9: 851–853.
Heisterkamp N, Stam K and Groffen J. . 1985 Nature 315: 758–761.
Hoffmann J, Pillaire M, Lesca C, Burnouf D, Fuchs R, Defais M and Villani G. . 1996 Proc. Natl. Acad. Sci. USA 93: 13766–13769.
Kedar P, Lowy D, Widen S and Wilson S. . 1990 Mol. Cell. Biol. 10: 3852–3856.
Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A and Rotter V. . 1989 Blood 74: 2318–2324.
Kunkel T. . 1985 J. Biol. Chem. 260: 5787–5796.
Laneuville P, Sun G, Timm M and Vekemans M. . 1992 Blood 80: 1788–1797.
LeMaistre A, Lee M, Talpaz M, Kantarjian H, Freireich E, Deisseroth A, Trujillo J and Stass S. . 1989 Blood 73: 889–891.
Loeb L. . 1991 Cancer Res. 51: 3075–3079.
Mandanas R, Leibowitz D, Gharehbaghi K, Tauchi T, Burgess G, Miyazawa K, Jarayam H and Boswell H. . 1993 Blood 82: 1838–1847.
Mashal R, Shtalrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujillo J, Gutterman J and Deisseroth A. . 1990 Blood 75: 180–189.
McCarthy D, Rassool F, Goldman J, Graham S and Birnie G. . 1984 Lancet 2: 1362–1365.
Rowley J. . 1973 Nature 243: 290–293.
Sawyers C, McLaughlin J and Witte O. . 1995 J. Exp. Med. 181: 307–313.
Scanlon K, Kashani-Sabet M and Miyashi H. . 1989 Cancer Invest. 7: 581–587.
Sobol R, Horton J, Kühn R, Gu H, Singhal R, Prasad R, Rajewsky K and Wilson S. . 1996 Nature 379: 183–186.
Wada C, Shionoya S, Fujino Y, Tokuhiro H, Akahoshi T, Uchida T and Ohtani H. . 1994 Blood 83: 3449–3456.
Wind ND, Dekker M, Berns A, Radman M and Riele HT. . 1995 Cell 82: 321–330.
Zmudzka B, Fornace A, Collins J and Wilson S. . 1988 Nucleic Acids Res. 16: 9589–9596.
Acknowledgements
This work was supported by La Ligue contre le Cancer – Comité de la Haute-Garonne (grants to YC and JSH). l'Association pour la Recherche sur le Cancer (grant to JSH) and by La Ligue Nationale contre le Cancer (grant to AGT).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Canitrot, Y., Lautier, D., Laurent, G. et al. Mutator phenotype of BCR – ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase β. Oncogene 18, 2676–2680 (1999). https://doi.org/10.1038/sj.onc.1202619
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202619
Keywords
This article is cited by
-
BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability
Leukemia (2013)
-
Genomic Instability in Chronic Myeloid Leukemia: Targets for Therapy?
Current Hematologic Malignancy Reports (2012)
-
Comparison of cellular responses across multiple passage numbers in Ba/F3-BCR-ABL cells induced by silver nanoparticles
Science China Life Sciences (2012)
-
Insights into the stem cells of chronic myeloid leukemia
Leukemia (2010)
-
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells
Oncogene (2008)